Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany
Open Access
- 26 December 2024
- journal article
- research article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (3) , 341-354
Abstract
Summary: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T‐cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C‐C chemokine receptor 4 (CCR4)‐directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second‐line treatment of stage IB and above SS and MF, after at least one prior systemic therapy. Since then, new insights on safety and efficacy of mogamulizumab were generated by post hoc analyses and real‐world evidence. A panel of CTCL‐experts discussed available literature and own experiences and developed relevant recommendations on the use of mogamulizumab in clinical practice in Germany. The recommendations cover patient criteria, prior therapies, use of mogamulizumab as monotherapy or combination therapy, management of side effects, duration of therapy, and monitoring schedules. The aim of these clinical recommendations is to support healthcare professionals in their decision‐making and use of mogamulizumab in daily practice.Keywords
This publication has 64 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysisInternational Journal of Hematology, 2024
- Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2022
- Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and ManagementDermatology and Therapy, 2021
- Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary SyndromeAdvances in Radiation Oncology, 2021
- Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary SyndromeJAMA Dermatology, 2021
- CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driverEuropean Journal of Immunology, 2021
- Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphomaJournal of Cancer Research and Clinical Oncology, 2020
- Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristicsCytometry Part B: Clinical Cytometry, 2020
- Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical ResponseJAMA Dermatology, 2019
- Antibody-Based Therapies for Cutaneous T-Cell LymphomaAmerican Journal of Clinical Dermatology, 2018